Oral ABX464 reduces the HIV DNA reservoir IN CD4+ peripheral blood T cells
Steens, J.-M., Cranston, R., Martinez-Picado, J., Paredes, R., Clotet, B., Gineste, P., Ehrlich, H., McGowan, I.
Published in Journal of Virus Eradication (01.12.2017)
Published in Journal of Virus Eradication (01.12.2017)
Get full text
Journal Article
POS0688 PHASE 2A STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO MTX AND/OR ANTI-TNFΑ THERAPEUTICS SHOWS THAT ORAL ABX464 50 MG ONCE DAILY IS SAFE, WELL TOLERATED AND SHOWS PROMISING EFFICACY RESULTS
Daien, C., Krogulec, M., Gineste, P., Steens, J. M., Desroys Du Roure, L., Biguenet, S., Scherrer, D., Santo, J., Ehrlich, H., Durez, P.
Published in Annals of the rheumatic diseases (01.06.2022)
Published in Annals of the rheumatic diseases (01.06.2022)
Get full text
Journal Article
OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
Vermeire, S, Hébuterne, X, Napora, P, Wisniewska-Jarosinska, M, Kiss, G, Bourreille, A, Przemysław, Z, Nitcheu, J, Gineste, P, Steens, J-M, Ehrlich, H
Published in Journal of Crohn's and colitis (25.01.2019)
Published in Journal of Crohn's and colitis (25.01.2019)
Get full text
Journal Article